Unknown

Dataset Information

0

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.


ABSTRACT: Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonstrated a tolerable safety profile. In this phase 2, open-label, multicentre clinical trial, 35 patients with relapsed and/or refractory MM following 1-3 prior therapies, including at least one bortezomib-based regimen, received carfilzomib 20 mg/m(2) in a twice-weekly, consecutive-day dosing schedule for ?12 monthly cycles. The best overall response rate (ORR) was 17·1% and the clinical benefit response rate (ORR + minimal response) was 31·4%. The median duration of response was >10·6 months and the median time to progression was 4·6 months. The most common adverse events were fatigue (62·9%), nausea (60·0%), and vomiting (42·9%). No exacerbation of baseline peripheral neuropathy was observed. Single-agent carfilzomib was generally well tolerated for up to 12 treatment cycles and showed activity in patients with relapsed and/or refractory MM who had received prior treatment with bortezomib. These data, combined with an acceptable toxicity profile, support the potential use of carfilzomib in patients with relapsed and/or refractory MM and warrant continued investigation of carfilzomib as single agent or in combination with other agents.

SUBMITTER: Vij R 

PROVIDER: S-EPMC5818209 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij Ravi R   Siegel David S DS   Jagannath Sundar S   Jakubowiak Andrzej J AJ   Stewart Alexander Keith AK   McDonagh Kevin K   Bahlis Nizar N   Belch Andrew A   Kunkel Lori A LA   Wear Sandra S   Wong Alvin F AF   Wang Michael M  

British journal of haematology 20120730 6


Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonstrated a tolerable safety profile. In this phase 2, open-label, multicentre clinical trial, 35 patients with relapsed and/or refractory MM following 1-3 prior therapies, including at least one bortezomib-based regimen, received carfilzomib 20 mg/m(2) in a twi  ...[more]

Similar Datasets

| S-EPMC4123327 | biostudies-literature
| S-EPMC7839365 | biostudies-literature
| S-EPMC4020895 | biostudies-literature
| S-EPMC4123387 | biostudies-literature
| S-EPMC4643003 | biostudies-literature
| S-EPMC8191071 | biostudies-literature
| S-EPMC7873303 | biostudies-literature
| S-EPMC4759707 | biostudies-other
| S-EPMC6386751 | biostudies-literature
| S-EPMC8259066 | biostudies-literature